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To determine if HPV immunisation has affected the prevalence of HPV genotypes and 
colposcopic features of CIN in young women referred for colposcopy. 
 
Design 
A two-centre observational study including vaccinated and unvaccinated women. 
 
Setting 
Colposcopy clinics serving two health regions in Scotland, UK. 
 
Population 
361 women aged 20-25 years attending colposcopy following an abnormal cervical 
cytology result at routine cervical screening.  
 
Methods 
Cervical samples were obtained from women for HPV DNA genotyping and mRNA 
E6/E7 expression of HPV 16,18,31,33 and 45. Demographic data, cytology and 
histology results and colposcopic features were recorded. Chi squared analysis was 
conducted to identify associations between vaccine status, HPV genotypes and 
colposcopic features. 
 
Main outcome measures 





The prevalence of HPV 16 was significantly lower in the vaccinated (8.6%) compared 
with the unvaccinated (46.7%) group (p=0.001). The number of cases of cervical 
intraepithelial neoplasia 2 or more (CIN2+) was significantly lower in vaccinated 
women (p=0.006).HPV vaccine did not have a statistically significant  effect on 
commonly recognised colposcopic features but there was a slight reduction in the 




In this group of young women with abnormal cytology referred to colposcopy, HPV 
vaccination via a catch-up programme reduced the prevalence of CIN2+ and HPV 16 
infection. The reduced PPV of colposcopy for the detection of CIN2+ in vaccinated 
women is at the lower acceptable level of the UK national cervical screening 
programme guidelines. 
Word count 246 
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Tweetable Abstract 
Reduction of hrHPV positivity and CIN in immunised women consistent with lower PPV 





HPV immunisation has been a major advance in the prevention of cervical disease 
and cancer. In September 2008, the bivalent vaccine (which protects against HPV 16 
and 18) was introduced in the UK as part of the school-based immunisation 
programme.1 The vaccine is given to girls aged 12-13 years and current uptake rate 
in schools in Scotland is 90%.2 When the vaccine was introduced, it was also offered 
to girls aged 14-17 as part of a catch up campaign: 65.5% of the eligible catch up 
group in Scotland received the full three doses.2Within the school vaccination 
programme the bivalent vaccine was used initially (2008-2010) but since 2011 it was 
changed to the quadrivalent vaccine.  
 
While prophylactic HPV vaccines offer primary protection against the highest risk HPV 
types, as well as a level of cross protection for other high risk HPV types (HPV 
31,33,45)3.  However, there will still be a residual risk of disease conferred by other 
high risk HPV genotypes which are not covered by the currently licensed vaccine(s). 
Therefore, there is a continued need for secondary prevention using cervical screening 
and colposcopy.  
 
In Scotland cervical screening, using liquid based cytology, is offered to all women 
aged 20-60 years with referral to colposcopy for further investigation if the cytology 
shows high grade dyskaryosis or repeated low grade dyskaryosis or borderline nuclear 
abnormalities (BNA).4,5 HPV triage is not part of the screening programme in Scotland. 
 
There is inconsistent evidence as to whether the appearance of the cervix during 
colposcopy is influenced by the HPV genotypes present.6-9 A study by Jeronimo et al. 
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found that colposcopic features characteristic of high grade cervical intraepithelial 
neoplasia (CIN) imply infection with HPV 16 but not necessarily other HPV types.6 It 
has also been shown that lesions missed during colposcopy are more likely to be HPV 
16 negative than HPV 16 positive.7,8 In contrast, van der Marel et al. showed that the 
visual appearance of high grade HPV16 lesions at colposcopy is not different from 
lesions associated with other high risk HPV genotypes.9However, these studies do not 
include women who had been vaccinated against HPV infection. If the appearance of 
the cervix is associated with HPV genotypes present, it would be anticipated that HPV 
vaccination might alter the range of features seen at colposcopy and thereby 
potentially affect the performance of colposcopy.   
 
In this study, we investigated cervical abnormalities, HPV genotypes and performance 
of conventional colposcopic evaluation in both vaccinated and unvaccinated women 
aged 20-25 years attending colposcopy. 
 
Methods 
Study design and population: This two centre cross-sectional study was conducted 
with women aged 20-25 years routinely attending colposcopy clinics following an 
abnormal cervical cytology result in two Scottish teaching hospitals (Aberdeen Royal 
Infirmary and Edinburgh Royal Infirmary) serving regional populations. The first group 
(Group 1) of women was recruited between February 2010 and March 2011(before 
women vaccinated as part of the catch-up immunisation campaign had entered the 
cervical screening programme) and the second group (Group 2) of women was 
recruited from December 2012 to November 2014 (after women vaccinated as part of 
the catch up campaign had entered the screening programme).Some individuals 
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(2008-2010) will have received Gardasil, through private arrangement, out with the 
catch up programme. 
 
 
Recruitment& Consent: Women were eligible if they attended colposcopy for the first 
time following an abnormal cytology result at routine cervical screening. Women were 
excluded if they were unable to understand the patient information leaflet (PIL), if they 
were pregnant at the time of colposcopy or if they were being referred as a 
consequence of symptoms.  Eligible women were sent an invitation letter and 
information before attending for colposcopy.  At their appointment, written consent was 
obtained if they wished to take part in the study. 
 
Data collection: Participants were assigned a unique study number and data were 
collected on age, referral cytology, parity and vaccination status (including vaccine 
type, number of doses and age at last dose). Women were considered to be 
vaccinated if they received two or more doses of a HPV vaccine.10Information on 
vaccine status was obtained from the Scottish Cervical Call-Recall System (SCCRS). 
SCCRS is the national cervical screening database that contains cytology results, 
associated histopathology, recall and management data and also immunisation status. 
 
Colposcopy:Colposcopy was performed by BSCCP-accredited colposcopists, who 
recorded their findings using standard reporting features.Colposcopists were blind to 
the HPV status of the patient. Samples for HPV genotyping were obtained using a 
broom sampler before the application of acetic acid and were stored in ThinPrep® 
PreservCyt®(©Hologic UK, Crawley, West Sussex, UK).Biopsies were taken if 
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features indicative of CIN were seen at colposcopy, including acetowhite changesand 
capillary vessel patterns A ‘see and treat’ approach was considered for women 
referred with high grade dyskaryosis, as per local protocols.  If a punch biopsy or 
diathermy loop excision treatment was undertaken, these had a histological diagnosis 
within the local NHS pathology laboratory.  Histology results were captured from 
pathology records. 
 
HPV genotyping: Samples were tested at the Scottish HPV Reference Laboratory, 
Edinburgh for the presence of 37 HPV genotypes using QIAamp® Media 
MDx11followed by LINEAR ARRAY HPV Genotyping Test (Roche Molecular 
Systems).12High-risk HPV types were considered to be: 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59 and 68. Intermediate risk HPV types were: 26, 53, 64, 66, 67, 69, 70, 
73, 82, IS39 and CP6108. All other HPV genotypes that were identified were 
considered to be low-risk.13 
 
A sub-set of samples (N=319;88%), based on availability of samples, were also tested 
for mRNA expression using PreTect HPV-Proofer (Norchip AS, Klokkarstua, Norway) 
which detects E6/E7 mRNA from HPV 16, 18, 31, 33 and 45.14 
 
 
Statistical analysis: All statistical analyses were performed using SPSS Version 20 
(IBM SPSS Statistics for Windows, Version 20.0, Armonk, NY: IBM Corp.) Chi-squared 
analysis was used to test for associations between vaccine status and colposcopic 
features, colposcopic opinion, histology results and HPV genotypes. All p values were 
two sided and for the chi-squared analysis were considered significant if their value 
8 
 
was less than 0.05.  Z-tests of two proportions were used to assess the difference in 
prevalence for each of the 35 types genotyped. As multiple statistical tests were 
conducted, the significance threshold for the z-tests was subject to the Bonferroni 
correction and therefore considered significant if their value was less than 0.00143 
(=0.05/35). 
 
Performance analysis of colposcopy was conducted using histology results as the gold 
standard for final diagnosis.  In cases where no biopsy was indicated, women were 
assumed to have no significant disease.  Sensitivity, specificity, PPV and NPV of 
colposcopy were calculated for detection of high grade disease (CIN2+); a positive 
test was considered to be a colposcopic opinion of “high grade”. Comparisons were 
made between vaccinated and unvaccinated women, and also between those who 
were positive and those who were negative for DNA HPV16.  Differences in the 
performance of colposcopy between groups were assessed using z-tests. 
 
Statistical power: Power analysis was conducted to calculate how many participants 
were necessary to reach adequate sample size using EPISTAT software.  The 
proportion of high risk types was estimated from previously published research.13 A 
1:1 ratio for HPV 16/18 against all other HPV types was used. It was estimated 400 
women would give 95% power to detect a reduction in PPV of colposcopy from 70% 
to 52.5% between 200 HPV16/18 positive women and 200 women who did not have 
HPV16/18.  If only 200 women in total were recruited (100 with and 100 without 






Figure S1: Flow diagram of recruitment and study processes 
A flow diagram of recruitment and study processes is included in supplementary 
information. In Group 1 (recruited before women eligible for the HPV vaccine in the 
catch up campaign entered the cervical screening programme) 208 women agreed to 
participate,10 were excluded because they did not have a sample taken for HPV 
testing.  Of the 198 women included in the final analysis, 172 had both HPV mRNA 
and DNA tests. In Group 2 (recruited after women eligible for the HPV vaccine in the 
catch up campaign entered the cervical screening programme) 175 women agreed to 
take part, 12 were excluded because they did not have a sample for HPV testing or 




Table S1shows the participant characteristics for each group. Vaccine status was self-
reported in Group 1 (three women (2%) reported being vaccinated: two received the 
quadrivalent vaccine and one received the bivalent vaccine).As this could not be 
verified by SCCRS at the time, all women were considered unvaccinated. In Group 2 
the vaccine status was verified by SCCRS and 67 (41%) women were vaccinated. The 
mean age at colposcopy in both groups was 22 years.  For those vaccinated, the mean 
age at last dose was 17.3years (SD1.2).  
Table 1: Participant Demographic data by group 
 
Impact of vaccination on colposcopic features and histology 
Table 2: Impact of vaccination status on colposcopic features and histology 
10 
 
As shown in Table 2, the proportions of women with acetowhite changes (79% vs 
77%), mosaic (44% vs 43%), punctation (38% vs 39%)or atypical vessels(1% vs 1%) 
were similar in both unvaccinated and vaccinated groups respectively. There was no 
significant impact on non-iodine staining epithelium, which is noted in a higher 
proportion of vaccinated women (56%) compared to unvaccinated women (50%; 
p=0.44). However, the use of iodine was inconsistent between colposcopists, and was 
not applied in 100 cases limiting any conclusions. Colposcopists were significantly 
more likely to record their opinion as high grade in unvaccinated women (34%) 
compared to vaccinated women (20%; p=0.027), a difference of 14% (95% CI 2%, 
26%).  Unvaccinated women were also more likely to have high grade disease (CIN2+) 
36%, compared to 19% in vaccinated women, p=0.006; a difference of 17% (95% CI 
5%, 29%).  Unvaccinated women were also more likely to have any grade of CIN 
(CIN1+); 63% compared to 46% in vaccinated p=0.044, a difference of 17% (95% CI 
2%, 30%). 
 
All eight cases of invasive squamous carcinoma or CGIN were identified in 
unvaccinated women. All three cases of CIN3 identified in vaccinated womenwere 
HPV 16 and 18 negative on cervical samples; two of these were associated with HPV 
33 (mRNA and DNA positive) and one with HPV 52(DNA positive). A higher proportion 
of vaccinated women (40% compared with 28% unvaccinated) did not have a biopsy 
taken (i.e. the colposcopic appearance did not indicate any significant disease).  
 
HPV Genotyping Results 
Figure 1: HPV genotyping results 
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Figure 1 demonstrates the HPV genotypes that were present in vaccinated and 
unvaccinated women. Only six vaccinated women (9%) had HPV 16, a significantly 
lower proportion than the unvaccinated group (47%; p<0.001). Two (3%) of the 
vaccinated women had an HPV 18 infection, compared to 17% of the unvaccinated 
women (p=0.003). High risk HPV types 52, 56 and 58 were found to be present in a 
higher proportion of women in the vaccinated group than in the unvaccinated 
group(23% vs 13%;p = 0.039, 16% vs 6%;p=0.023 and 13% vs 6%;p=0.029 
respectively).The changes in HPV 18, 52, 56 and 58 are not considered statistically 
significant when multiple statistical testing is accounted for.  For all other high risk HPV 
types, there was no difference in prevalence between vaccinated and unvaccinated 
women. 
 
319 samples were tested for HPV mRNA (HPV 16, 18, 31, 33 or 45), 172 in Group 1 
and 147 in Group 2. Although 14 (25%) samples in the vaccinated group had a 
transcriptionally active HPV infection indicated by the mRNA results, there was a 
significantly higher proportion of women in the unvaccinated group (63%) with 
transcriptionally active HPV infections (p<0.001). Of the vaccinated group, four (7%) 
tested positive for HPV 16 mRNA compared to 101 (38%) of the unvaccinated group 
(p<0.001).   
 
Impact of HPV 16 infection on Colposcopic Features and histology 
Table S1 in supplementary information shows colposcopic features and histology 
results by HPV 16 status  
There was no association between presence of HPV 16 DNA or HPV16 mRNA and 
any individual colposcopic features.  Despite this, colposcopists were more likely to 
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record a colposcopic opinion of high grade if participants were HPV 16 DNA positive 
(57%;p=0.006) or HPV 16 mRNA positive (59%;p=0.03) than if the woman was HPV16 
DNA/mRNA negative (37% and 43% respectively). Women were also more likely to 
have a high grade histology result if they were positive for HPV 16 DNA (71%;p<0.001) 
or HPV 16 mRNA (77%;p<0.001) than if they tested negative (38% and 43% 
respectively). 
 
Performance of colposcopy 
Table 3: Impact of HPV vaccine and HPV 16 on performance of colposcopy  
Table 3summarises the performance of colposcopy in vaccinated and unvaccinated 
women in terms of sensitivity, specificity, PPV and NPV for the detection of CIN2+.The 
HPV vaccination status did not have a statistically significant impact on the 
performance of colposcopy. The PPV of colposcopy was 74.0 (95% CI: 63.8-82.1) in 
unvaccinated women and 66.7 (95% CI: 35.4-88.7)in vaccinated women although this 
difference was not statistically significant (p=0.591).  
 
HPV 16 presence or absence had a significant impact on the specificity and NPV of 
colposcopy for detecting high grade disease (p<0.001).   Colposcopy was found to 
have a higher specificity (92.4 (95% CI: 87.1-95.7) compared to 75.0 (95%CI: 62.3-
84.6)) and NPV (94.6 (95% CI: 89.7-97.3) compared to 64.9 (95% CI: 52.8-75.4)) in 










Vaccination in the catch-up cohort is associated with a significant reduction in the 
prevalence of HPV 16/18 and CIN2+ in women aged 20-25 years attending 
colposcopy in Scotland3. Our results show that colposcopic features were similar in 
vaccinated and unvaccinated women and differences were related to the incidence of 
cervical disease. Our results indicate that the performance of colposcopy in vaccinated 
women has not diminished substantially. However, the PPV for CIN2+ was lower in 
vaccinated women (albeit not at a statistically significant level). 
 
Strengths and Limitations 
To our knowledge, this study is the first to investigate the impact of HPV genotypes on 
colposcopic features associated with CIN in HPV immunised women. This is possible 
as cervical screening in Scotland starts earlier than in many countries, with vaccinated 
women entering our national programme in 2010. Scotland achieved high rates of 
vaccination in the catch up campaign (65.5%) and has reasonable3 yearly cervical 
screening uptake (70.7% overall, 50.9% in 20-24 year olds).15For Group 2 we were 
able to assign vaccine status using SCCRS to improve reliability. 
 
To minimise bias, colposcopists and histopathologists were blinded to HPV results and 
staff undertaking the HPV genotyping tests were blinded to vaccine status.  
 
As the aim of the immunisation is to reduce deaths from cervical cancer, it could be at 
least age 30 before this can be confidently measured. The long lead–time between 
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HPV infection and development of malignancy means that high grade CIN (as used in 
our study) is a justifiable surrogate marker for cervical cancer.16 
 
Where the cervix appeared normal, biopsies were not taken (as per local protocols) 
so these women lacked a “gold standard diagnosis” and were classified as ‘disease 
negative’ for analysis. A high proportion of women who did not have a biopsy taken 
were subsequently found to be HPV 16 negative. This resulted in a high NPV of 
colposcopy for detecting high grade disease in HPV 16 negative women, despite there 
being no histological confirmation of disease status for them. The NPV of colposcopy 
has been previously been recorded as high (up to 96%), so we expect to miss very 
few cases of CIN.17,18 
 
However, as Jeronimo et al.6 suggested that high grade CIN is more likely to be missed 
by colposcopy in the absence of HPV 16, it may be that the HPV 16 negative women 
with normal colposcopy have disease lacking characteristic colposcopic features. 
Follow up of our cohort in the future will address this.  
 
Interpretation 
We believe this is the first study conducted with this primary aim in women who have 
received HPV vaccine.6-9Previousstudies reporting on the impact of HPV genotypes 
on colposcopy were conducted as ad hoc analyses of larger studies with inconsistent 
results. Jeronimo et al. found that HPV 16 was more likely to produce lesions with 
colposcopically identifiable features than other HPV types, regardless of histology.6 
Louwers et al. reported the presence of HPV 16 significantly improved the sensitivity 
of the Dynamic Spectral Imaging colposcopy for CIN and hypothesised that HPV 16 
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is associated with acetowhitening.7Using data from this same study, Zaal et al. found 
that HPV 16 did not impact the performance of standard colposcopy and suggested 
that effects were dependent on the underlying grade of disease, rather than HPV16 
per se.8Similarly, van der Marel found that the visual appearance of high-grade HPV16 
lesions did not differ from lesions associated with other high-risk HPV types.9 Our 
results support this with no significant difference in relation to either vaccine status or 
presence of HPV16. Changes in PPV relate to the reduced incidence of high grade 
disease in immunised women as PPV is strongly influenced by disease prevalence 
and the reduction reflects the reduction in CIN.19With the emerging cohort of women 
who received HPV immunisation as part of routine vaccination, rather than catch up, 
it is important to clarify the effect of reducing or even eliminating HPV vaccine types 
from the screened population as we use colposcopy to identify and treat CIN. 
 
We did not find any association between HPV 16 and acetowhitening in women 
attending colposcopy. Colposcopists were able to identify HPV 16 negative lesions 
during colposcopy which were confirmed on biopsy. The women included in our study 
were younger (mean age 22.3 years) compared with previous studies (mean age 
ranged from 26.2 to 36.7 years).6-9Given that the peak prevalence of HPV infection 
occurs in women beforethat of CIN, we anticipate that the impact of HPV genotypes 
on colposcopic features may also vary according to age.20 
 
The vaccinated women in this study received the HPV immunisation as part of the 
catch up campaign. The mean age at last dose was 17.3 years. Women were not 
asked about sexual activity. It is likely that some women were sexually active and 
therefore not HPV naïve prior to vaccination.3,21,22 
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Our study suggests that, compared to unvaccinated women, lower proportions of 
vaccinated women had high grade cervical cytology. A similar observation has been 
made in Australia.16 This study reported a significant decrease (38%; p=0.003) in high 
grade cervical abnormalities in young girls (under 18 years) following the introduction 
of the HPV vaccine but no significant decrease in the incidence of low grade cervical 
abnormalities in this age category, or in women aged 18-20 years. As the cohort 
vaccinated in the school programme at age 12 enters screening, in 2021 in the UK, 
we would expect to see a greater impact on PPV with lower disease rates if we do not 
review risk stratification of our screening policy. 
 
Our results are consistent with those reported in the screened population in Scotland 
with a significant reduction in circulating HPV vaccine types and associated 
diseaseand provides further evidence of the success of the vaccination 
programme.3,20,23 The prevalence of HPV16/18 in vaccinated women attending 
colposcopy is similar to that in young women attending cervical screening (11.5% at 
colposcopy compared to 11% and 13.6% at screening).3,23 Kavanagh et al. found that 
HPV 51 and 56 were the most prevalent HPV genotypes in vaccinated women 
attending cervical screening (10.5% and 9.6% respectively).3The prevalence of HPV 
51 and 56 was higher in the vaccinated women attending colposcopy compared to the 
unvaccinated women (15.7% for each compared to 12.7% and 5.8% respectively in 
unvaccinated women) in our study. In contrast to Kavanagh et al, we found that HPV 
52 and 59 emerged as the most prevalent HPV genotypes in vaccinated women 
attending colposcopy with abnormal cytology (22.9% and 17.1% respectively). 
However different HPV assays were used in those studies which may influence HPV 




We found no significant impact of vaccination on colposcopic features in women aged 
20-25 with abnormal cervical cytology who had received the HPV 16/18 vaccine as 
part of a catch up campaign. Despite the lower prevalence of HPV 16 in vaccinated 
women, features considered characteristic of high grade CIN were still detectable. 
Cervical screening needs to continue to offer protection from disease from non-
vaccine types. However, the reduction in prevalence of CIN has impacted on the PPV 
of colposcopy and this has implications for quality assurance of colposcopy in the 
cervical screening programme.  
 
In order to assess the impact of the HPV vaccination on colposcopy performance 
further, studies should be conducted when the women who received the vaccine as 
part of the school based immunisation programme (in whom the coverage rates were 
90%) enter the cervical screening programme.  
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Figure 1: Flow diagram of recruitment 
Group 1 
208 consented to participate 
Group 2 
175 consented to participate 
 
10 excluded because no 
sample or insufficient material 
for HPV genotyping 
198 included in final analysis 
12 excluded because: 
11 had no sample or insufficient material 
for HPV genotyping 
1 had missing data proforma  
163 included in final analysis 
172 had HPV 
mRNA  and 
DNA testing 
26 had HPV 
DNA testing 
only 
147 had HPV 
mRNA  and 
DNA testing 




Figure 2: HPV genotyping results from samples collected at colposcopy 
Table 1: Participant demographic data by group 
 Group 1 N (column %) 
N=198* 







96 (58.9 ) 
Site 
Site 1 95 (48.0) 53 (79.1) 93 (96.9) 241 (66.8) 
Site 2 103 (52.0) 14 (20.9) 3 (3.1) 120 (33.2) 
Age at colposcopy 
20 years 42 (21.2) 17 (25.4) 5 (5.2) 64 (17.7) 
21 years 33 (16.7) 31 (46.3) 5 (5.2) 69 (19.1) 
22 years 29 (14.6) 14 (20.9) 18 (18.8) 61 (16.9) 
23 years 39 (19.7) 3 (4.5) 31 (32.3) 73 (20.2) 
24 years 40 (20.2) 1 (1.5) 17 (17.7) 58 (16.1) 
25 years 15 (7.6) 1 (1.5) 20 (20.8) 36 (10.0) 
Mean Age (years) 22.2 (SD 1.6) 21.2(SD 1.0) 23.2 (SD 1.4) 22.3 (SD 1.6) 
Referral Cytology 
Borderline 46 (23.2) 19 (28.4) 27 (28.1) 92 (25.5) 
Mild dyskaryosis 86 (43.4) 34 (50.7) 28 (29.2) 148 (41.0) 
Moderate dyskaryosis 36 (18.2) 12 (17.9) 28 (29.2) 76 (21.1) 
Severe dyskaryosis 24 (12.1) 2 (3.0) 11 (11.5) 37 (10.2) 
Glandular neoplasia 1 (0.5) - 2 (2.1) 3 (0.8) 
Invasive cancer 1 (0.5) - - 1 (0.3) 
Missing 4 (2) - - 4 (1.1) 
Histology 
Biopsy not taken± 61 (30.8) 27 (40.3) 20 (20.8) 108 (29.9) 
Normal (No CIN) 19 (9.6) 9 (13.4) 10 (10.4) 38 (10.5) 
CIN1 53 (26.8) 18 (26.9) 24 (25.0) 95 (26.3) 
CIN2 35 (17.7) 9 (13.4) 23 (24.0) 67 (18.6) 
CIN3 24 (12.1) 3 (4.5) 14 (14.6) 41 (11.4) 
Invasive squamous 1a1 1 (0.5) - 1 (1.0) 2 (0.6) 
CGIN 2 (1.0) - 4 (4.2) 6 (1.7) 
Unsatisfactory 3 (1.5) 1 (1.5) - 4 (1.1) 
Table 1: Comparison of participant demographics between groups."Vaccinated" women refer to women 
who had received 2 or more doses of the HPV vaccination. *Group 1 includes 3 women who reported they 
had received the HPV vaccine.  ±All cases where biopsy was not taken were because colposcopic 
appearances were normal. 
  










Acetowhite 231/291 (79.4) 54/70 (77.1) 0.623 
Mosaic 129/291 (44.3) 30/70 (42.9) 0.791 
Punctation 111/291 (38.1) 27/70 (38.6) 1.00 
Atypical Vessels 3/291 (1.0) 1/70 (1.4) 0.589† 
Iodine Negative** 101/202 (50.0) 33/59 (55.9) 0.442 
Colposcopic Opinion 
High Grade*** 99/290 (34.1) 13/66 (19.7) 0.027 
Histology**** 
CIN2+ 103/286 (36.0) 13/69 (18.8) 0.006 
CIN1+ 179/286 (62.6) 32/69 (46.3) 0.044† 
Table 2 compares the features seen at colposcopy between all participants regardless of disease status 
who were vaccinated against HPV 16 and 18, and women who were not. It also compares the colposcopic 
opinion and histology results between these groups. In patients where biopsies were not taken, they were 
considered to have no disease.*Pearson’s test used unless otherwise indicated. †Fisher’s exact test used. 
**in 100 cases, iodine was not used. This was for a variety of reasons including patient allergy or 
colposcopist preference. ***High grade colposcopic opinion was appearance suggestive of CIN2+. 
****Histology results were “unsatisfactory” for 5 unvaccinated and 1 vaccinated therefore were excluded 
from histology analysis.  










 HPV 16+ 
(95% CI) 
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Table 3: Predictive values of colposcopy for detecting high grade disease where histology results were 
considered "gold standard" and the test was colposcopic opinion. This has been done to compare 
predictive values between vaccinated and unvaccinated participants and between participants who are 
HPV 16 positive and negative.  
  
3: Impact of HPV 16 on colposcopic features and histology  
 
HPV 16 DNA + 
n/N (%) 















Acetowhite 105/109 (96.3) 104/107 (97.2) 1.00
† 85/87 (97.7) 103/107 (96.3) 0.693
† 
Mosaic 69/109 (63.3) 63/107 (58.9) 0.58 56/87 (64.4) 64/107 (59.8) 0.554 
Punctation 61/107 (57.0) 55/107 (51.4) 0.49 50/86 (58.1) 55/106 (51.9) 0.466 
Atypical Vessels 2/107 (1.9) 1/106 (0.9) 1.00
† 2/85 (2.4) 1/106 (0.9) 0.586
† 
Iodine Negative 46/109 (42.2) 44/108 (40.7) 0.41 37/87 (42.5) 49/108 (45.4) 0.853 
Colposcopic Opinion 
High Grade 61/108 (56.5) 40/107 (37.4) 0.006 51/86 (59.3) 46/107 (43.0) 0.03 
Histology 
CIN2+ 77/108 (71.3) 39/103 (37.9) <0.001 67/87 (77.0) 45/104 (43.3) <0.001 
Table 3 compares colposcopic features, colposcopic opinion and histology results between participants 
with cervical disease (CIN1+) by HPV 16 DNA status, and by HPV 16 mRNA status. Iodine was not used in 
31 participants who were HPV 16 DNA+, 24 HPV 16 DNA-, 24 mRNA+, 26mRNA-. *Pearson’s test used unless 
otherwise indicated. †Fisher’s exact test used. 
 
 
 
